[Renal cell carcinoma: which criteria to define antiangiogenic treatment failure? A case report].
Failure criteria of antiangiogenic treatment that must make envisage a change of molecule are still difficult to define. Concerning the evaluation of the response, if the RECIST criteria seem to be limited, several other tools of evaluation (clinical, radiological or biological tools) can be interesting. It is the case of contrast-enhanced ultra-sonography, but a precise definition of functional parameters should be defined and a standardization of the technique is necessary. Side effects do not translate necessarily a treatment failure. They must be estimated by taking into account the frequency of some of symptoms. Asthenia is noticed in more than 50% of the patients ; it is however necessary to exclude another aetiology, in particular iatrogenic hypothyroidism.
Lang
H
H
Service d'Urologie, CHU de Strasbourg, place de l'Hôpital, Strasbourg cedex, France.
Lassau
N
N
Thibault
F
F
Delva
R
R
Pignot
G
G
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017211:Treatment Failure
D020533:Angiogenesis Inhibitors